These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

954 related articles for article (PubMed ID: 29319167)

  • 1. Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy.
    Nasiri H; Valedkarimi Z; Aghebati-Maleki L; Majidi J
    J Cell Physiol; 2018 Sep; 233(9):6441-6457. PubMed ID: 29319167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-targeted drugs and drug resistance--challenges and solutions.
    Shefet-Carasso L; Benhar I
    Drug Resist Updat; 2015 Jan; 18():36-46. PubMed ID: 25476546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Advances in Site Specific Conjugations of Antibody Drug Conjugates (ADCs).
    Gao W; Zhang J; Xiang J; Zhang L; Wu C; Dhal PK; Chen B
    Curr Cancer Drug Targets; 2016; 16(6):469-79. PubMed ID: 27174056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
    Yamada K; Ito Y
    Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody drug conjugates: Progress, pitfalls, and promises.
    Mukherjee A; Waters AK; Babic I; Nurmemmedov E; Glassy MC; Kesari S; Yenugonda VM
    Hum Antibodies; 2019; 27(1):53-62. PubMed ID: 30223393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-Drug Conjugates: The New Frontier of Chemotherapy.
    Ponziani S; Di Vittorio G; Pitari G; Cimini AM; Ardini M; Gentile R; Iacobelli S; Sala G; Capone E; Flavell DJ; Ippoliti R; Giansanti F
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32752132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Design of next generation antibody drug conjugates].
    Zhu GD; Fu YX
    Yao Xue Xue Bao; 2013 Jul; 48(7):1053-70. PubMed ID: 24133971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-Drug Conjugates for Cancer Therapy.
    Hafeez U; Parakh S; Gan HK; Scott AM
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33081383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-drug conjugates: Principles and opportunities.
    Phuna ZX; Kumar PA; Haroun E; Dutta D; Lim SH
    Life Sci; 2024 Jun; 347():122676. PubMed ID: 38688384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Picking the optimal target for antibody-drug conjugates.
    Mathur R; Weiner GJ
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement.
    Jiang M; Li Q; Xu B
    Drug Resist Updat; 2024 Jul; 75():101086. PubMed ID: 38677200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential.
    Ceci C; Lacal PM; Graziani G
    Pharmacol Ther; 2022 Aug; 236():108106. PubMed ID: 34990642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to Antibody-Drug Conjugates.
    García-Alonso S; Ocaña A; Pandiella A
    Cancer Res; 2018 May; 78(9):2159-2165. PubMed ID: 29653942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive review on the elaboration of payloads derived from natural products for antibody-drug conjugates.
    Lu N; Wu J; Tian M; Zhang S; Li Z; Shi L
    Eur J Med Chem; 2024 Mar; 268():116233. PubMed ID: 38408390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-drug conjugates for targeted cancer therapy: Recent advances in potential payloads.
    Xi M; Zhu J; Zhang F; Shen H; Chen J; Xiao Z; Huangfu Y; Wu C; Sun H; Xia G
    Eur J Med Chem; 2024 Oct; 276():116709. PubMed ID: 39068862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigational antibody drug conjugates for solid tumors.
    Sapra P; Hooper AT; O'Donnell CJ; Gerber HP
    Expert Opin Investig Drugs; 2011 Aug; 20(8):1131-49. PubMed ID: 21599617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent Advances in Antibody-Drug Conjugates for Breast Cancer Treatment.
    Deng S; Lin Z; Li W
    Curr Med Chem; 2017; 24(23):2505-2527. PubMed ID: 28554322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of Resistance to Antibody-Drug Conjugates.
    Loganzo F; Sung M; Gerber HP
    Mol Cancer Ther; 2016 Dec; 15(12):2825-2834. PubMed ID: 27780876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions.
    Yu J; Li M; Liu X; Wu S; Li R; Jiang Y; Zheng J; Li Z; Xin K; Xu Z; Li S; Chen X
    Biomed Pharmacother; 2024 May; 174():116522. PubMed ID: 38565055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.
    Vezina HE; Cotreau M; Han TH; Gupta M
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S11-S25. PubMed ID: 28921650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.